Anti-CD19 CAR-T / First Affiliated Hospital of Nanchang University - LARVOL DELTA

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study (ASH 2025) - P4 | "Background: CD19 CAR-T cells have changed the treatment landscape for relapsed/refractory non-Hodgkin lymphoma (R/R NHL) offering a potential curative-intent strategy. In this subgroup analysis of the real-world study, axi-cel demonstrated effectiveness and tolerability in patients with R/R NHL, both in those younger than than 65 years and those aged 65 years or older. Notably, patients aged ≥65 exhibited numerically higher CR rates and improved PFS compared to younger patients (aged <65), with a manageable safety profile. These findings further support the broader use of axi-cel in older patients with R/R NHL."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population (ASH 2024) - P2 | "The chimeric antigen receptor (CAR-T) cell therapy has revolutionized the treatment of relapsed/refractory (R/R) B-cell ALL, with the first FDA-approved product, Kymriah (tisagenlecleucel) developed by Novartis, significantly improving remission rates and survival times. pCAR-19B is an autologous CAR-T cell product with an optimized humanized CD19-specific single-chain variable fragment (scFv) designed to address safety concerns...Conclusions : Despite a heavy burden of BM blasts and a high risk of genetic variations, pCAR-19B demonstrated high remission rates, achieved a high rate of MRD-negative remission, durable responses, and a tolerable safety profile. This study represents the first pivotal clinical trial of childhood B-ALL in an Asian population, offering a new treatment option for Chinese pediatric and young adult patients with R/R B-ALL."

Clinical • P2 data • Acute Lymphocytic Leukemia • Childhood B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Solid Tumor

Efficacy and Safety of CD19-Specific CAR-T Cell Therapy Following Immunochemotherapy in Newly Diagnosed B-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (ASH 2023) - "We assessed the effectiveness and safety of autologous anti-CD19 CAR-T cell therapy following an immunochemotherapeutic regimen based on R-DEP (Rituximab-doxorubicin-etoposide-methylprednisolone) as a first-line treatment option for patients with B-LAHS. Importantly, no exacerbation of hemophagocytic syndrome occurred following CAR-T cell infusion, and no patients succumbed to adverse events. In conclusion, our findings suggest that CD19 CAR-T cell treatment exhibits high efficacy as part of first-line therapy for B-LAHS, with a manageable safety profile."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Rare Diseases

Efficacy and safety of dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B-cell lymphoid malignancies: a systematic review and meta-analysis. (PubMed, Hum Gene Ther) - "Dual-targeting chimeric antigen receptor (CAR)-T cell therapy has been proposed as a potential solution for overcoming antigen escape during anti-CD19 CAR-T treatment...This study demonstrates the safety and clinical efficacy of dual-targeting CAR-T cell therapies in B-cell malignancies. Further well-designed randomized controlled trials are required to establish the role of dual-targeting CAR-T cell therapy in patients with B-cell malignancies."

Journal • Retrospective data • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology